Tag Archive for: Hospira

Cathy Srebalus-Barnes, PhD Joins Hospira as Senior Director, Bioanalytical Sciences

Former Director, Bioproduct Analytical Development at

Eli Lilly and Company

Life Science Partner announces the recruitment of Cathy Srebalus-Barnes, PhD, an experienced bioanalytical executive, to become Senior Director, Bioanalytical Sciences, Global Biologics R&D for Hospira, Inc.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

In her new role at Hospira, Inc., Srebalus-Barnes will lead a global scientific team responsible for bioanalytical method development and bioanalytical characterization activities supporting Hospira’s growing biosimilars pipeline.

Srebalus-Barnes has spent much of her career at Eli Lilly and Company, where she was most recently responsible for leading three teams of scientists that included Analytical Development, Trace Analysis and Bioassay groups.  She oversaw the complete downstream process for Phase II – ready for III preparation for therapeutic biotechnology products in clinical and commercial development.  Previously, Srebalus-Barnes served as Director, Bioprocess Virology and Purification Development, where she was responsible for two groups managing the purification process development and viral safety procedures for all biotechnology products in development.

Barnes earned a Bachelor of Science Degree in Chemistry from West Virginia University and her Doctorate from Indiana University in Analytical Chemistry.

/0 Comments/by

Thomas Nikolai to Join Hospira as Senior Director, External Biologics Collaborations and Partnerships

Life Science Partner recruits former Director, Biologics, Parenteral Products at Abbott Laboratories

Life Science Partner announces the recruitment of Thomas Nikolai, MS, MBA, to become Senior Director, External Biologics Collaborations and Partnerships for Hospira’s biosimilars division.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

Nikolai leaves Abbott with over 20 years of leadership experience in biologics process development, technical operations and manufacturing support.  In his most recent role, Nikolai served as Director, Biologics, Parenteral Products, where he was the Global CMC leader for commercial and late-stage biologic drug products including Humira, Abbott’s blockbuster arthritis drug.

“Nikolai is a passionate and results-driven professional with a progressive technical management career in the biopharmaceutical industry.” noted Tom Callaway, MD, Founder and President of Life Science Partner.  “He brings a wealth of knowledge and leadership to the biologics team at Hospira and will serve the company well as it provides biosimilar versions of the world’s most critical biological drugs.”

Nikolai received his Bachelor of Science Degree in Chemical Engineering and Bioengineering from the University of Wisconsin, Madison and his Masters of Science in Biochemical Engineering from the University of Minnesota, Twin Cities.  He earned a Masters in Business Administration from the University of Wisconsin, Parkside.

/0 Comments/by

Peter Lacouture Joins Hospira as Medical Director, Pain Management

Life Science Partner Recruits Pain Clinical Specialist from Purdue Pharma and Co-Founder of Magidom Discovery

Life Science Partner announces the recruitment of Peter Lacouture, PhD, to become Medical Director of Pain Management for Hospira.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.  The company recently acquired Javelin Pharmaceuticals to take advantage of the synergies between Javelin’s main product candidate, DylojectTM ,a post-operative pain management drug and Hospira’s proprietary sedation agent PrecedexTM.

In 2001, Lacouture co-founded Magidom Discovery, a pharmaceutical services company focused on all aspects of research and development for pain management drug development.  This followed his long tenure at Purdue Pharma where he served as the Senior Director of Clinical Research.  In his new role at Hospira, Lacouture will have overall responsibility for the clinical development of the expanding portfolio of pain drugs under development, as well as leading the decision process regarding the potential clinical utility and regulatory strategy of pain management compounds.

“Lacouture has a strong background in clinical development of acute pain drugs – both as the leader of compounds in development in a major leader in the space, as well as with small companies as a consultant,” noted Tom Callaway, MD, President of Life Science Partner.  “His considerable network of key opinion leaders in the space will serve Hospira well as it continues to expand it considerable portfolio of pain managements drugs and systems.”

Lacouture earned a Bachelor of Arts degree in Chemistry from the College of Holy Cross, Worcester.  He received his Masters in Pharmacology/Toxicology and his PhD in Pharmacology/Physiology from the Massachusetts College of Pharmacy and Allied Health Sciences, Boston.

/0 Comments/by

Neil Schauer, PhD joins Hospira as Senior Director, Biologics Process Development

Life Science Partner recruits former Director of DSP Research and Development at Millipore Corp

Life Science Partner announces the recruitment of Neil Schauer, PhD, a seasoned biopharmaceutical development leader and scientist, to become Senior Director, Biologics Development for Hospira’s biosimilars division.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

In his most recent role at Millipore Corp, Schauer was responsible for scientific and managerial leadership of a large research and development organization with four functional areas focusing on DSP Research.  Prior to his tenure at Millipore Corp, Schauer served as the Director of Cambridge Manufacturing Sciences at Biogen Idec.  In his new role at Hospira, he will have overall responsibility for providing strategic and technical leadership to a large staff of pharmaceutical scientists responsible for the development of Drug Substance and Drug Product manufacturing for Hospira’s biosimilar products.

“Schauer is a versatile leader and scientist with a solid background in managing large teams in the identification and development of disruptive new technologies” noted Tom Callaway, MD, Founder and President of Life Science Partner.  “With his global knowledge and reach, he will serve Hospira well in its mission to become a global leader in providing biosimilar versions of the world’s most critical biological drugs.”

Schauer earned a Bachelor of Science in Biochemistry and Biology and his PhD in Anaerobic Microbiology from the Virginia Polytechnic Institute, Blacksburg.

/0 Comments/by

Dr. Scott Treiber joins Hospira as Vice President of Clinical Operations and Medical Affairs

Life Science Partner recruits former Executive Vice President at inVentiv Clinical Solutions

Life Science Partner announces the recruitment of Scott Treiber, PhD, an experienced clinical research leader, to Hospira to become Vice President of Clinical Operations and Medical Affairs.

Hospira is a $5 B global specialty pharmaceutical and medication delivery company based in Lake Forest, Illinois.

Previously Treiber served as Executive Vice President Clinical Development at inVentiv Clinical Solutions.  He had responsibility for all aspects of clinical monitoring and project management, including executive project oversight and client interaction for full service clinical trials managed by the company.   Earlier Treiber held senior-level positions at leading Contract Research Organizations, including PharmaNet, Quintiles, ICON and Premier Research.

“Treiber has a depth of experience in clinical development organizational management in a wide range of therapeutic categories including neuroscience, cardiovascular, general medicine and oncology,” noted Tom Callaway, MD, President of Life Science Partner.  “His global CRO background will serve the company well as it transforms its business to a more diversified pharmaceutical company including a portfolio of biosimilar drugs.”

Treiber earned his Bachelor of Science Degree in Biology from the University of Iowa and his PhD in Biology from the University of California Santa Cruz.  He completed his MBA from Ellis College, New York Institute of Technology.

/0 Comments/by

Seema Kumbhat, MD, joins Hospira as Medical Director, Device Development – Clinical Decision Support

Life Science Partner recruits former Vice President, Medical Affairs at McKesson Provider Technologies

Life Science Partner announces the recruitment of Seema Kumbhat, MD to Hospira to become Medical Director, Device Development – Clinical Decision Support.

Hospira is a $5 B global specialty pharmaceutical and medication delivery company based in Lake Forest, Illinois.   In this new role, she will be responsible for the customer-relations and the clinical-insights into Hospira’s increasingly sophisticated drug delivery systems.

Kumbhat comes well prepared for the role, as she has led clinical teams and customer relationships in the leading healthcare IT companies.  As Vice President of Medical Affairs at McKesson Provider Technologies, Kumbhat served as the key clinical liaison across large healthcare systems and physician practices for the company.

Earlier, Kumbhat served as Enterprise Clinical Manager and Physician Consultant for GE Healthcare IT Solutions where she managed a team of content experts in software configuration for specific clinical specifications.  She joined industry directly from her surgical residency program to help EPI Systems develop their surgery, anesthesia and enterprise medical record systems.

“Kumbhat is articulate and passionate about making healthcare IT solutions that serve the physicians and hospital-based caregivers with efficiency and real-world solutions,” noted Tom Callaway, MD, President of Life Science Partner.  “Her broad background as a physician liaison and her direct experience in the field of product development and customer support will be a great asset to the Medical Device team at Hospira”

Kumbhat earned her Bachelor of Science Degree (Magna cum Laude) from the University of Miami and her Medical Degree with Research Distinction in Surgery at the University of Miami School of Medicine.

/0 Comments/by

Tom Vanden Boom to join the Hospira as Global Pharmaceuticals Vice President of Biologics R&D

Life Science Partner recruits former Director of the Biologics Manufacturing Launch Teams at Bristol-Myers Squibb Company

Life Science Partner announces the recruitment of Tom Vanden Boom, PhD, a senior biopharmaceutical executive in the development, manufacturing and commercial launch of biologic products.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

In his most recent role at Bristol-Myers Squibb, Vanden Boom was responsible for leading the Biologics Manufacturing Launch Teams for global technical operations manufacturing and supply chain activities supporting the commercial launch of all new biologic products for the company.   Prior to his tenure at Bristol-Myers Squibb, Vanden Boom served as the Department Head of Biological Development at Abbott Laboratories.  In his new role at Hospira, he will provide strategic and technical leadership for the company’s drive to develop biosimilars drugs for some of the world’s blockbuster biological drugs.

“Vanden Boom is a talented strategic leader with an established track record of building highly successful teams and managing complex biological projects,” noted Tom Callaway, President of Life Science Partner.  “His considerable technical and business expertise in the development of biopharmaceuticals will serve Hospira well in its mission to become a global leader in providing biosimilar versions of the world’s most critical biological drugs.”

Vanden Boom earned a Bachelor of Science degree in Biochemistry and a Masters in Bacteriology from the University of Wisconsin – Madison.  He received his PhD in Microbiology from the University of Illinois at Urbana-Champaign.  There, he also completed a post-doctoral in Molecular Genetics.

/0 Comments/by

Hospira Recruits Kurt Gunter, MD, to Lead Cell Therapy Initiatives

Life Science Partner recruit offers valuable experience in regulatory and commercialization strategy

Life Science Partner announces the recruitment of Kurt C. Gunter, MD, as medical director, cell therapy of Hospira, a Chicago area based medical products company.  Hospira is a specialty pharmaceutical and medication delivery company launched from the core global hospital products business of Abbott Laboratories. 

With the recruitment of Gunter, Hospira now has a leader in the field of cell therapy to provide scientific and medical leadership for technology assessment and investment, and manage key relationships with academic and research institutions.  He will have the critical responsibility for representing the cell-therapy companies seeking investment and/or partnership.

“Kurt has a broad background in cell and gene therapy – with a specific expertise in developing regulatory guidelines for the field,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “Few can match his experience in the use of cells for new therapies that hold out the promise to cure intractable diseases.”

As the vice president and medical affairs/governmental relations of ZymeQuest, Gunter led the clinical strategy of a biotechnology company removing A and B antigens from red blood cells to create “universal donor” blood.  Previously, he held a similar role at ViaCell, a cord blood banking and cell therapy company.  His first commercial experience was as vice president, clinical and regulatory for Transkaryotic Therapies (TKT) supervising all regulatory filings for its orphan drug program.

His earlier career was as a researcher and clinical pathologist at Children’s National Medical Center, George Washington University Medical School, and the FDA, where he was acting director, division of cellular and gene therapy.  A recognized leader in the field, he was appointed as the industry representative to the standards-setting organization, the FDA Cellular Tissue and Gene Therapy Advisory Committee.

Gunter earned his BS at Stanford and his MD at University of Kansas School of Medicine, where he also completed his residency.  He continued his anatomical pathology training at University of Maryland and was a biotechnology fellow in molecular immunology at the National Cancer Institute.

/0 Comments/by